Evidence map›Paper›PMID 39465409›Full record

ArticleBMC research notes2024

The silent predictors: exploring galectin-3 and Irisin's tale in severe COVID-19.

Valentina N Nikolic, Višeslav Popadic, Slobodan M Jankovic, Nenad Govedarović, Stevan Vujić, Jelica Andjelković, Lazar S Stosic, Nikola Č Stevanović, Marija Zdravkovic, Zoran Todorovic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Galectins and Liver Diseases.International journal of molecular sciences · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Valentina N Nikolic *Department of Pharmacology with Toxicology, University of Nis Faculty of Medicine, Bul. dr Zorana Djindjica 81 Nis, Nis, 18000, Serbia. valentina@medfak.ni.ac.rs.
Višeslav PopadicUniversity Hospital Medical Center, Bezanijska kosa, Belgrade, Serbia.
Slobodan M JankovicDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Nenad GovedarovićDepartment of Internal Medicine, University of Nis Faculty of Medicine, Nis, Serbia.
Stevan VujićUniversity of Nis Faculty of Medicine, Nis, Serbia.
Jelica AndjelkovićUniversity of Nis Faculty of Medicine, Nis, Serbia.
Lazar S StosicUniversity of Nis Faculty of Medicine, Nis, Serbia.
Nikola Č StevanovićUniversity of Nis Faculty of Medicine, Nis, Serbia.
Marija ZdravkovicUniversity Hospital Medical Center, Bezanijska kosa, Belgrade, Serbia.
Zoran Todorovic *University Hospital Medical Center, Bezanijska kosa, Belgrade, Serbia.

Funding

Ministry of Education, Science and Technological Development, Republic of Serbia 451-03-66/2024-03/200113
6 · The paper itself

Abstract

objectiveThis study aimed to evaluate the roles of galectin-3 and irisin as biomarkers in predicting severe outcomes in COVID-19 patients.

resultsWe analyzed serum levels of galectin-3 and irisin in 59 patients with severe COVID-19 and 30 healthy controls. Elevated galectin-3 levels were associated with increased risks of mortality, need for intensive care, and severe acute respiratory distress syndrome. The optimal cut-off value for galectin-3 was 13.47 ng/ml, with a sensitivity of 72.7% and specificity of 76.6%. Irisin levels did not differ significantly between survivors and non-survivors at admission or on the 3rd day post-admission, but approached significance on the 7th day. These findings suggest that galectin-3 could be a valuable prognostic biomarker for severe COVID-19 outcomes, while irisin's role remains to be clarified in further studies.

Indexed as

BiomarkersCOVID-19FibronectinsGalectin 3AdultAgedBlood ProteinsCase-Control StudiesFemaleGalectinsHumansMaleMiddle AgedPrognosisRespiratory Distress SyndromeSARS-CoV-2BiomarkersBlood ProteinsFibronectinsFNDC5 protein, humanGalectin 3GalectinsLGALS3 protein, humanBiomarker discoveryCOVID-19 prognosisGalectin-3IrisinSARS-CoV-2 infection

Identifiers

PMID39465409
PMCPMC11514771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.